IL303518A - Mutations orthogonal to heterodimerization - Google Patents

Mutations orthogonal to heterodimerization

Info

Publication number
IL303518A
IL303518A IL303518A IL30351823A IL303518A IL 303518 A IL303518 A IL 303518A IL 303518 A IL303518 A IL 303518A IL 30351823 A IL30351823 A IL 30351823A IL 303518 A IL303518 A IL 303518A
Authority
IL
Israel
Prior art keywords
domain
amino acid
sequence
domains
mutation
Prior art date
Application number
IL303518A
Other languages
English (en)
Hebrew (he)
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of IL303518A publication Critical patent/IL303518A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
IL303518A 2020-12-10 2021-12-10 Mutations orthogonal to heterodimerization IL303518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063123915P 2020-12-10 2020-12-10
PCT/US2021/062951 WO2022125986A1 (en) 2020-12-10 2021-12-10 Orthogonal mutations for heterodimerization

Publications (1)

Publication Number Publication Date
IL303518A true IL303518A (en) 2023-08-01

Family

ID=81974005

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303518A IL303518A (en) 2020-12-10 2021-12-10 Mutations orthogonal to heterodimerization

Country Status (10)

Country Link
US (2) US12312418B2 (https=)
EP (1) EP4259194A4 (https=)
JP (1) JP2024500354A (https=)
KR (1) KR20230118612A (https=)
CN (1) CN116867514A (https=)
AU (1) AU2021397322A1 (https=)
CA (1) CA3207821A1 (https=)
IL (1) IL303518A (https=)
MX (1) MX2023006899A (https=)
WO (1) WO2022125986A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JP6385357B2 (ja) * 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2016130516A1 (en) * 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
JP7438942B2 (ja) * 2017-10-30 2024-02-27 エフ． ホフマン－ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
KR102870868B1 (ko) * 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
JP7812230B2 (ja) * 2019-04-25 2026-02-09 エフ． ホフマン－ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
AU2021224883A1 (en) * 2020-02-20 2022-09-29 Invenra Inc. Bispecific GD2 and B7H2 binding molecules and methods of use

Also Published As

Publication number Publication date
AU2021397322A9 (en) 2024-06-20
WO2022125986A1 (en) 2022-06-16
AU2021397322A1 (en) 2023-07-06
KR20230118612A (ko) 2023-08-11
EP4259194A1 (en) 2023-10-18
JP2024500354A (ja) 2024-01-09
US20260078202A1 (en) 2026-03-19
US20220363782A1 (en) 2022-11-17
CN116867514A (zh) 2023-10-10
EP4259194A4 (en) 2025-03-19
US12312418B2 (en) 2025-05-27
MX2023006899A (es) 2023-09-04
CA3207821A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
JP6385357B2 (ja) 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
IL322472A (en) Humanized antibodies against c-kit
IL243311B (en) New frameworks for antibodies
IL271128B1 (en) New anti-3CD antibodies
IL317013A (en) Binding proteins are activated under limited conditions
IL295749A (en) Bispecific molecules binding gd2 and b7h2 and methods of use
JP7760377B2 (ja) タンパク質を多量体化する変異体ドメイン及びその分離
IL295729A (en) Bispecific engineered anti-2her proteins, preparations containing them and their uses
IL287291B (en) A protein that binds to rgma and its use
JP7123063B2 (ja) 抗体ドメインの好ましい対形成
IL297847A (en) Anti-pd-l1 antibody and its use
IL270308B2 (en) Anti-interferon gamma antibodies and their uses
IL303518A (en) Mutations orthogonal to heterodimerization
IL271127B1 (en) New anti-HSA antibodies
IL284317B1 (en) Pseudofab-based multispecific binding proteins
CA3210307A1 (en) Bispecific antibody
IL323768A (en) Anti-cd28 x anti-trop2 antibodies
IL323870A (en) Antibodies against x cd28 and anti enpp3
IL310700A (en) Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
IL298076A (en) Multispecific antibodies
IL321347A (en) Fusion comprising anti-tau antibody and peptide and use thereof
IL322940A (en) Multivalent anti-spike protein binding molecules and their uses
IL294714A (en) Anti-nkp30 antibodies and methods of use